Literature DB >> 11821231

Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri.

Takao Mukai1, Tomoko Asasaka, Eri Sato, Kenichi Mori, Mitsuyo Matsumoto, Hitoshi Ohori.   

Abstract

We examined the competition of binding of Lactobacillus reuteri and Helicobacter pylori to gangliotetraosylceramide (asialo-GM1) and sulfatide which are putative glycolipid receptor molecules of H. pylori, and identified a possible sulfatide-binding protein of the L. reuteri strain. Among nine L. reuteri strains, two (JCM1081 and TM105) were shown to bind to asialo-GM1 and sulfatide, and to inhibit binding of H. pylori to both glycolipids by a thin layer chromatogram-overlay assay using biotin-labeled bacterial cells. The extract from the bacterial cells of strain TM105 with several detergents, including octyl beta-D-glucopyranoside, retained binding to both glycolipids and also inhibited H. pylori binding, suggesting that a binding inhibitor(s) is associated with the bacterial cell surface. When the cell extract was applied to the agarose gel immobilized galactose 3-sulfate corresponding to the structure of sugar moieties of sulfatide, an approximately 47-kDa protein was found to bind to the gel. This observation strongly suggested that inhibition by selected L. reuteri strains help to prevent infection in an early stage of colonization in H. pylori and proposed that L. reuteri strains sharing glycolipid specificity with H. pylori have a potential as probiotics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11821231     DOI: 10.1111/j.1574-695X.2002.tb00541.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  61 in total

Review 1.  Fighting fire with fire: is it time to use probiotics to manage pathogenic bacterial diseases?

Authors:  John Heineman; Sara Bubenik; Stephen McClave; Robert Martindale
Journal:  Curr Gastroenterol Rep       Date:  2012-08

2.  Lactobacillus reuteri in the treatment of Helicobacter pylori infection.

Authors:  Maria Pina Dore; Marianna Cuccu; Gianni Mario Pes; Alessandra Manca; David Yates Graham
Journal:  Intern Emerg Med       Date:  2013-11-01       Impact factor: 3.397

Review 3.  Role of sulfatide in normal and pathological cells and tissues.

Authors:  Tadanobu Takahashi; Takashi Suzuki
Journal:  J Lipid Res       Date:  2012-05-22       Impact factor: 5.922

4.  Peptide Extracts from Cultures of Certain Lactobacilli Inhibit Helicobacter pylori.

Authors:  Luc De Vuyst; Pascal Vincent; Eleftherios Makras; Frédéric Leroy; Bruno Pot
Journal:  Probiotics Antimicrob Proteins       Date:  2010-03       Impact factor: 4.609

5.  Live Lactobacillus rhamnosus [corrected] is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression.

Authors:  Donglai Ma; Paul Forsythe; John Bienenstock
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

Review 6.  Probiotics for the treatment of Helicobacter pylori infection in children.

Authors:  Lucia Pacifico; John Frederick Osborn; Enea Bonci; Sara Romaggioli; Rossella Baldini; Claudio Chiesa
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

7.  Lactobacilli inhibit interleukin-8 production induced by Helicobacter pylori lipopolysaccharide-activated Toll-like receptor 4.

Authors:  Chao Zhou; Feng-Zhen Ma; Xue-Jie Deng; Hong Yuan; Hong-Sheng Ma
Journal:  World J Gastroenterol       Date:  2008-08-28       Impact factor: 5.742

8.  Effects of multispecies probiotic combination on helicobacter pylori infection in vitro.

Authors:  E Myllyluoma; A-M Ahonen; R Korpela; H Vapaatalo; E Kankuri
Journal:  Clin Vaccine Immunol       Date:  2008-06-25

Review 9.  Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials.

Authors:  Hao-Ran Fang; Guo-Qiang Zhang; Jing-Yi Cheng; Zhong-Yue Li
Journal:  Eur J Pediatr       Date:  2018-11-16       Impact factor: 3.183

10.  Lactic acid bacterial extracts as anti-Helicobacter pylori: a molecular approach.

Authors:  H El-Adawi; M El-Sheekh; M Khalil; N El-Deeb; M Hussein
Journal:  Ir J Med Sci       Date:  2013-02-13       Impact factor: 1.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.